RADNOR, Pa., Jan. 22, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge") (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering ("IPO") held on or about September 26, 2024 (the "Class Period"). The lead plaintiff deadline is March 10, 2025.CONTACT KESSLER TOPAZ MELTZER & CH ...

Lawsuit Overview - BioAge Labs is facing a class-action lawsuit from shareholders alleging the company misled investors about the safety and prospects of its key drug candidate, azelaprag, before its IPO [1][2] - The lawsuit claims BioAge's IPO offering documents contained "materially false and/or misleading" statements regarding the STRIDES Phase 2 clinical trial for azelaprag [2] - The company raised $227.7 million by selling 12.65 million shares at $18 each in its September 2024 IPO [2] Clinical Trial Issues - BioAge presented the STRIDES trial as free of safety concerns and predicted positive results, but halted the trial in December 2024 after participants experienced elevated liver enzymes [3] - The trial discontinuation caused BioAge's stock to plummet over 76%, dropping from the $18 IPO price to around $5.82 per share [4] Legal Allegations - Shareholders accuse BioAge and certain executives of violating the Securities Act of 1933 by making false statements in IPO documents [4] - The close timing between the IPO and trial discontinuation raises questions about the company's pre-IPO disclosures [5] Financial Impact - BioAge's stock price dropped significantly following the trial discontinuation announcement, with shares trading around $5.82 compared to the $18 IPO price [4]

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether BioAge and certain of its officers and ...

Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIOA ...

BENSALEM, Pa., Jan. 21, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BIOAGE LABS, INC., CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MARCH 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G. ...

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join- Contact Levi & Korsinsky ...

Shareholders That Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class Action - BIOA ...

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky ...

BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! ...